Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Abstract

A method for preparing multivalent proteosomeamphiphilic determinant vaccines suitable for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiplilic determinants include lipopolysaccharides from gram negative bacteria, e.g. S. flexneri, P. shigelloides and S. sonnei. Proteosomes are obtained from group B type 2b meningococci. The active proteosomeamphiphilic determinant complexes (noncovalently complexes) of the vaccine are formed using defiltration or ultrafiltration to remove the detergent. The use of diafiltration or ultrafiltration decreases processing time and the opportunity for contamination and further permits the use of ambient temperature and efficient scaleup. In addition, the process permits the reliable and continuous monitoring of the dialysate which enhances the efficiency of the entire process. The time of dialysis for production of a lot of vaccine is reduced from 710 days to less than 72 hours and usually less than 48 or 4 hours. The use of the process optimizes the presence of each antigenic component in the preparation of multivalent vaccines.

Description

1. FIELD OF THE INVENTION[0001] This invention concerns methods of production and compositions for non-covalently complexed multivalent proteosome vaccines for mucosal and parenteral administration.2. BACKGROUND OF THE INVENTION[0002] In order for multivalent sub-unit vaccines to stimulate optimal immune responses to each of the components, the proper components should be appropriately associated and each be available to the immune system so that they may be efficiently recognized and processed by cells of the immune system. Prime examples of such non-covalently complexed vaccines include proteosome vaccines which can consist of neisserial outer membrane protein proteosomes non-covalently complexed to a wide variety of antigens including peptides, lipopeptides, transmembrane or toxoided proteins, polysaccharides or lipopolysaccharides (LPS) (patent application Ser. Nos. 07 / 065,440 filed Jun, 23, 1987 "Immunogenic peptide vaccines and methods of preparation"; 07 / 336,952 filed Apr. 12...

AI Technical Summary

Benefits of technology

[0008] The present invention provides methodology to produce non-covalently complexed vaccines in a manner that 1) Decreases the time required, 2) Decreases the opportunity for contamination, 3) Increases the temperature to ambient temperature that such vaccines can be produced, 4) Allows for efficient scale-up of the production process so as to require minimum use of reagents, 5) Allows for reliable and efficient sampling of dialysate so as to be able to repeatedly measure rate of removal of the detergent so as to optimize efficiency of the operation. This leads directly to an increase in the complexing efficiency of vaccine so as to produce vaccine with measurably greater immunogenicity at lower doses. In this manner, the overall quality of the product is significantly enhanced. 6) In addition, a method is described to measure the presence of the detergent used in the preferred embodiment, Empigen BB. Other dialyzable detergents can be used in place of Empigen BB. Furthermore, using the method of the instant invention, it has been demonstrated that the vaccine can be lyophilized and re-hydrated in such a manner as to retain optimal vaccine potency as measured by vaccine immunogenicity.

Problems solved by technology

The practical disadvantages of this system tend to severely preclude the advanced development and commercialization of this technology for several reasons including 1) Time: Length of time of the procedure: The need to use GMP resources for weeks while the vaccine is dialyzing is impractical both due to the excess costs involved and the increased opportunity for breakdown or contamination of mechanical or biological components during this extended period of time; 2) Contamination: Increased opportunity for contamination: dialysis tubing is difficult to sterilize, dialysis tubing requires manually opening and closing the system thereby exposing the components to contamination during both the loading and unloading process.

Since many days transpire between loading and unloading the tubing, the risk of a small contamination in the initial days of the process may readily be magnified during the many days of dialysis to render this method useless for practical vaccine manufacture.

The risk of puncturing the bag can result in loss of product.

These amounts are wasteful and impractical compared to the method used in the instant invention; Dialysis tubing is not scalable since large amounts of product is problematic and 5) Inability to readily measure completeness of removal of the detergent so as to maximize vaccine effectiveness.

Since the dialysis bag is placed in a container with 200 volumes of buffer, the ongoing measurement of detergent removal is neither practical nor feasible and 6) In addition, no method has been described for the measurement of the presence of the detergent used in the preferred embodiment, Empigen BB.

Images